Wednesday, October 23, 2024
spot_img

Major shareholder announcement

Pursuant to Section 30 of the Danish Capital Markets Act, Novonesis hereby announces that BlackRock, Inc. has notified Novonesis of the following status relating to the position of share capital attached to shares and share capital through financial instruments.

Per October 22, 2024, BlackRock, Inc. has adjusted its holding of shares to an equivalent of 23,548,644 shares, corresponding to 5.02% (previously 4.92%) of the total share capital attached to shares. The combined total of share capital attached to shares and share capital through financial instruments is 5.05% (previously 5.01%).

Attachments

  • 2024_43_Major_Shareholders_Announcement
  • Novozymes B 22 Oct 2024 Final

Powered by SlickText.com

Hot this week

Alliance Witan PLC – Transaction In Own Shares

Alliance Witan PLCLEI: 213800SZZD4E2IOZ9W55  TRANSACTION IN OWN SHARES  Alliance Witan...

Weekly share repurchase program transaction details

October 23, 2024 SBM Offshore reports the transaction...

PayPoint plc : Director/PDMR Shareholding

23 October 2024 PayPoint plc ("the Company") ...

Transaction in Own Shares

Transaction in Own Shares 23 October, 2024 ...

Umicore – Transparency notifications by BlackRock, Inc. and by Bank of America Corp.

Transparency notifications by BlackRock, Inc. and by Bank of...

Topics

Alliance Witan PLC – Transaction In Own Shares

Alliance Witan PLCLEI: 213800SZZD4E2IOZ9W55  TRANSACTION IN OWN SHARES  Alliance Witan...

Weekly share repurchase program transaction details

October 23, 2024 SBM Offshore reports the transaction...

PayPoint plc : Director/PDMR Shareholding

23 October 2024 PayPoint plc ("the Company") ...

Transaction in Own Shares

Transaction in Own Shares 23 October, 2024 ...

Umicore – Transparency notifications by BlackRock, Inc. and by Bank of America Corp.

Transparency notifications by BlackRock, Inc. and by Bank of...

Daré Bioscience Selected to Receive $10 Million Award from ARPA-H’s Sprint for Women’s Health

DARE-HPV is a potential first-in-category treatment for human papillomavirus...

SYNERGIE : Q3 2024 REVENUES

Q3 2024 REVENUES In challenging market conditions, SYNERGIE...

2024 third quarter turnover: 131.1 million euros

2024 third quarter turnover: 131.1 million euros ...
spot_img

Related Articles

Popular Categories

spot_img